BCL-2-INHIBITOREN

European patent · EP3788042 · In force

Register entry

Publication number
EP3788042
Application number
EP19797052
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Apr 29, 2019
Published
Mar 10, 2021
Granted
Feb 12, 2025
Protection ends at the latest
Apr 28, 2039
Next annual fee due
Apr 30, 2027
IPC classes
C07D 403/12 (2006.01)
A61K 31/496 (2006.01)
A61P 35/00 (2006.01)
C07D 471/04 (2006.01)
A61K 31/437 (2006.01)
A61P 37/02 (2006.01)
Priority
WO PCT/CN2018/085217 29.04.2018
WO PCT/CN2018/107134 21.09.2018
PCT application
PCT/CN2019/085001 29.04.2019
PCT publication
WO2019/210828 07.11.2019
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. May 1, 2026

    Change

    Published in Swissreg on 01.05.2026

  2. Dec 24, 2025

    Change

    Published in Swissreg on 24.12.2025

  3. Nov 27, 2025

    Holder’s address changed

    Owner
    BeiGene Switzerland GmbH, Aeschengraben 27, 4051 Basel → BeOne Medicines I GmbH, Aeschengraben 27, 4051 Basel

    Published in Swissreg on 27.11.2025

  4. May 1, 2025

    Change

    Published in Swissreg on 01.05.2025

  5. Feb 26, 2025

    Agent entered

    Representative
    Murgitroyd & Company, Geneva Rhone 8 Sàrl, Rue du Commerce 4, 1204 Genève

    Published in Swissreg on 26.02.2025

  6. Feb 12, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 12.02.2025

Parties

Inventor

XUE, Hai

Beijing 102206, CN

WANG, Zhiwei

Beijing 102206, CN

SUN, Hanzi

Beijing 102206, CN

GUO, Yunhang

Beijing 102206, CN

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.